Evidence and support

Medication options and current availability

Medication can be effective and is not a moral failure. Sertraline has randomized trial evidence; zuranolone is an FDA-approved oral treatment for adults with postpartum depression. Clinical selection and precautions matter.

Research preview · selected sources rechecked September 14, 2026 · independent clinical review pending. These editorial assessments are not formal GRADE ratings. No study here establishes an effect of Brighter Postpartum.

The important distinction

Trials are not head-to-head rankings. Zuranolone has sedation and driving precautions. Brexanolone/Zulresso should not be advertised as routinely available in the US after withdrawal of approval effective April 14, 2025.

supportedtreatment · C23

Sertraline has randomized treatment evidence

Population and setting: 38 postpartum women, six-week placebo-controlled trial.
What was found: Response 59% versus 26%; remission 53% versus 21%.
Limits and applicability: Small trial, not a forecast for an individual. Prescribing, bipolar assessment, interactions and breastfeeding decisions require qualified care.

Sources: S35 · S05

promisingprevention · C24

Preventive medication may be considered after prior PPD

Population and setting: 22 women with a prior postpartum depressive episode.
What was found: Recurrence: 1/14 sertraline versus 4/8 placebo in a small pilot.
Limits and applicability: Specialist, high-risk planning—not a reason to prescribe to all postpartum women or to stop an effective existing treatment.

Sources: S36

supportedtreatment · C25

Zuranolone can improve PPD symptoms rapidly

Population and setting: Phase 3 trial of severe postpartum depression; earlier formulation.
What was found: Day-15 HAM-D change −17.8 versus −13.6; difference −4.2 points (95% CI −6.9 to −1.5).
Limits and applicability: FDA-approved oral course is 14 days; driving restriction and sedation precautions matter. Follow-up does not establish lifelong cure.

Sources: S37 · S38

supportedavailability · C26

Brexanolone listings need an availability correction

Population and setting: US regulatory status.
What was found: FDA withdrew Zulresso approval effective April 14, 2025 after the sponsor reported it was no longer marketed.
Limits and applicability: Historical trials remain evidence but should not be presented as a routine currently marketed US option.

Sources: S39

Can an app recommend a medicine or dose?

Not this product. Use a licensed clinician to assess severity, prior response, bipolar risk, feeding context, interactions and the full safety profile.

Use this as information, not an assessment

Symptoms or concerns deserve appropriate professional care. Severe or worsening symptoms should not wait for an app, a quiz or a two-week threshold.